Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

ries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... WV (PRWEB) June 19, 2013 The ... individual used the sauna but the overall experience for ... to be positive health-wise. , Mr Mouw, whose Virgina-based ... to the Society’s statement by saying that the type ... learned of a number of counterfeit imitations which frankly, ...
(Date:6/19/2013)... June 19, 2013 Researchers from the ... demonstrated several new studies at ENDO 2013, The ... June 15-18 in San Francisco.     , Mount Sinai researchers ... the role of prostastic acid phosphatase (PAP) in Prostate ... stimulate the thyroid gland; revealed the prevalence of primary ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 CCA ... of Dr. John Baxter to Vice President, Health Services, ... as Director, Mental Health Services for CCA. He ... an honor and great privilege to lead CCA's dedicated ... unique opportunity to serve society and our partners as ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... 2013 Citi Bike has come to New York ... David Perna to know for sure how many patients will choose ... they’ll have the option. In fact, he’s happy about anything ... also make it more convenient for them to visit his office ... of Complimentary Alternative Medicine at Back and Body Medical and an ...
Breaking Medicine News(10 mins):Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... leukemia, also shows promise against a type of stomach cancer ... a promising anti-leukemia drug for treatment of a relatively rare ... pill once a day, is effective in treating both forms ... cancer cells without attacking healthy cells and causing severe side ...
... mothers can modify the length of other women's menstrual ... mother - or their infants - made the cycles ... Ohio University.// ,She suggests this is due to ... as part of a human's desire to raise children ...
... Hopkins University School of Medicine have recently found that the ... that lets us stop smelling something, even though the odour ... issue of the journal Science show that a protein called ... job of these reurons is to detect smells and send ...
... immune cells which help protect us from disease does not ... it could be something to do with their shape. ... how immune cells behave in microgravity as part of their ... ,It has been found that astronauts have elevated virus levels ...
... The Federal Drug Administration approved OxyContin in late 1995 ... early 1996. Between that time and 2000, prescriptions for ... that they could get a powerful heroin-like high by ... powder.// ,Abuse of OxyContin, the nation's best ...
... Kava is derived from a leafy plant native to the ... implicated in approximately 25 cases of liver diseases. The herb ... to treat insomnia, anxiety, stress and muscle spasms. According to ... as// benzodiazepines but is not chemically related. ,Benzodiazepines have ...
Cached Medicine News:Health News:Immune cells halt round in space 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: